The FDA Has Cleared Cullinan Therapeutics' Investigational New Drug Application For CLN-978 And Its Global Phase 1 Trial May Proceed In The U.S. To Assess CLN-978 In Patients With Moderate To Severe Systemic Lupus Erythematosus
Portfolio Pulse from Benzinga Newsdesk
Cullinan Therapeutics has received FDA clearance for its investigational new drug application for CLN-978. The company can now proceed with a global Phase 1 trial in the U.S. to assess CLN-978 in patients with moderate to severe systemic lupus erythematosus.
October 16, 2024 | 11:02 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cullinan Therapeutics has received FDA clearance for its investigational new drug application for CLN-978, allowing a Phase 1 trial in the U.S. for systemic lupus erythematosus.
The FDA clearance is a significant milestone for Cullinan Therapeutics, as it allows the company to proceed with clinical trials for CLN-978. This development could lead to positive investor sentiment and potential stock price increase due to the advancement in their drug pipeline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100